Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$40.00 USD

40.00
1,107,980

+0.53 (1.34%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $40.00 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches

QIAGEN's (QGEN) new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.

QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access

With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.

QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness

QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Qiagen (QGEN) Up 1.1% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base

QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.

QIAGEN (QGEN) Earns Notable Recognitions in Sustainability

QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.

QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands

QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.

Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay

QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.

Sarepta Therapeutics (SRPT) Surges 16.7%: Is This an Indication of Further Gains?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.

QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes

QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.

Why Is Seattle Genetics (SGEN) Down 0.7% Since Last Earnings Report?

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Qiagen (QGEN) Up 9.9% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down

In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.

Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.